Abstract
IntroductionOnce-weekly subcutaneous semaglutide, a glucagon-like peptide-1 analog, is approved in the USA as an adjunct to diet and exercise for adults with inadequately controlled type 2 diabetes (T2D) to improve...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have